3 Efficacy and Safety of Semaglutide 2.4 mg Once-Weekly in Adults With Overweight or Obesity and Type 2 Diabetes (STEP 2)

Autor:	Iichiro Shimomura, Ole K. Jeppesen, Adie Viljoen, Louise Færch, Arash Pakseresht, Ildiko Lingvay, Sue D. Pedersen, Leigh Perreault, Melanie J. Davies, René Gollan, Julio Rosenstock, Thomas A. Wadden
Rok vydání:	2021
Předmět:	Pediatrics medicine.medical_specialty business.industry Semaglutide medicine Once weekly Type 2 diabetes Overweight medicine.symptom business medicine.disease Obesity
Zdroj:	Adipositas-Kongress 2021 – 37. Jahrestagung der Deutschen Adipositas-Gesellschaft e.V..
ISSN:	2567-6334
DOI:	10.1055/s-0041-1735690
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::f573cc71b5ce8f12da85da3d6c95853f https://doi.org/10.1055/s-0041-1735690 Zobrazit plný text záznamu